近日，国内体外诊断（IVD）领先企业亚辉龙生物科技股份有限公司宣布与脑机星链（Brain-Computer Starlink）签署合作框架协议，标志着其正式进军脑机接口与神经科技交叉领域。根据协议，双方将围绕神经退行性疾病（如阿尔茨海默病、帕金森病等）的早期筛查与辅助诊断展开深度合作，整合亚辉龙在免疫检测、分子诊断等方面的技术优势，以及脑机星链在脑电信号采集、人工智能算法和神经解码方面的前沿能力。此次合作旨在开发融合生物标志物检测与脑电数据分析的新型多模态诊断平台，提升神经系统疾病的精准识别与干预效率。作为IVD行业的创新代表，亚辉龙近年来持续拓展技术边界，此次跨界合作不仅体现了其对前沿医疗科技的战略布局，也为未来智慧医疗与个性化诊疗开辟了新路径。
Recently, YHLO Biotech Co., Ltd.—a leading Chinese in vitro diagnostics (IVD) company—announced the signing of a cooperation framework agreement with Brain-Computer Starlink, marking its official entry into the interdisciplinary field of brain-computer interfaces and neurotechnology. Under the agreement, both parties will collaborate closely on early screening and auxiliary diagnosis of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The partnership leverages YHLO’s strengths in immunoassays and molecular diagnostics alongside Brain-Computer Starlink’s expertise in EEG signal acquisition, AI-driven algorithms, and neural decoding. The goal is to develop an innovative multimodal diagnostic platform that integrates biomarker testing with brainwave data analysis, enhancing the precision and efficiency of neurological disease detection and intervention. As an innovation-driven IVD player, YHLO has been actively expanding its technological frontiers; this cross-sector collaboration reflects its strategic vision for cutting-edge medical technologies and paves the way for smarter, personalized healthcare solutions.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/9571.html